Table 4. Percentage of injected mosquitoes displaying eGFP expression in body tissues after coinjection of ONNV-eGFP and dsRNAs from AgAgo1, AgAgo3, AgAgo4, and AgAgo5 at 3 and 6 dpi.
| 3 dpi
|
6 dpi
|
|||||
|---|---|---|---|---|---|---|
| Treatment | Head | Thorax | Abdomen | Head | Thorax | Abdomen |
| ONNV-eGFP + no dsRNA | 10% (4/40) | 85% (34/40) | 0% (0/40) | 36% (14/44) | 93% (41/44) | 20% (9/44) |
| ONNV-eGFP + dsβgal | 34% (20/58) | 86% (50/58) | 34% (20/58) | 57% (30/53) | 89% (47/53) | 57% (30/53) |
| ONNV-eGFP + dsAgAgo1 | 16% (9/55) | 98% (54/55) | 32% (18/55) | 81% (26/32) | 97% (31/32) | 94% (30/32) |
| ONNV-eGFP + dsAgAgo3 | 55% (22/40) | 98% (39/40) | 78% (31/40) | 75% (29/39) | 100% (39/39) | 80% (31/39) |
| ONNV-eGFP + dsAgAgo4 | 38% (20/52) | 94% (49/52) | 56% (29/52) | 73% (25/34) | 100% (34/34) | 82% (28/34) |
| ONNV-eGFP + dsAgAgo5 | 46% (24/52) | 98% (51/52) | 48% (25/52) | 62% (22/36) | 94% (34/36) | 42% (15/36) |